Trial Profile
A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer; Male breast cancer; Meningeal carcinomatosis
- Focus Therapeutic Use
- 07 Feb 2023 Planned End Date changed from 1 Sep 2023 to 22 Jul 2024.
- 19 Nov 2021 According to a Seagen media release, data from this study will be at the San Antonio Breast Cancer Symposium (SABCS), taking place December 7-10, 2021
- 23 Jun 2021 Status changed from recruiting to active, no longer recruiting.